239 related articles for article (PubMed ID: 15979321)
21. Treatment of myelodysplastic syndromes in elderly patients.
Sanchez JF
Adv Ther; 2011 Mar; 28 Suppl 2():1-9. PubMed ID: 21431504
[TBL] [Abstract][Full Text] [Related]
22. Update on the therapy for myelodysplastic syndrome.
Kasner MT; Luger SM
Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
[TBL] [Abstract][Full Text] [Related]
23. Optimal sequencing of treatments for patients with myelodysplastic syndromes.
Itzykson R; Fenaux P
Curr Opin Hematol; 2009 Mar; 16(2):77-83. PubMed ID: 19468268
[TBL] [Abstract][Full Text] [Related]
24. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
25. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
26. Myelodysplasia: when to treat and how.
Larson RA
Best Pract Res Clin Haematol; 2006; 19(2):293-300. PubMed ID: 16516126
[TBL] [Abstract][Full Text] [Related]
27. Practical use of azacitidine in higher-risk myelodysplastic syndromes: an expert panel opinion.
Fenaux P; Bowen D; Gattermann N; Hellström-Lindberg E; Hofmann WK; Pfeilstöcker M; Sanz G; Santini V
Leuk Res; 2010 Nov; 34(11):1410-6. PubMed ID: 20609474
[TBL] [Abstract][Full Text] [Related]
28. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Suwanawiboon B; Sumida KN
Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Kantarjian H; Beran M; Cortes J; O'Brien S; Giles F; Pierce S; Shan J; Plunkett W; Keating M; Estey E
Cancer; 2006 Mar; 106(5):1099-109. PubMed ID: 16435387
[TBL] [Abstract][Full Text] [Related]
30. Current State of the Art: Management of Higher Risk Myelodysplastic Syndromes.
Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S39-43. PubMed ID: 27521322
[TBL] [Abstract][Full Text] [Related]
31. Treating myelodysplastic syndromes.
Ryan C; McCann S
IDrugs; 2005 Apr; 8(4):320-6. PubMed ID: 15800807
[TBL] [Abstract][Full Text] [Related]
32. Current therapeutic approaches for patients with myelodysplastic syndromes.
Greenberg PL
Br J Haematol; 2010 Jul; 150(2):131-43. PubMed ID: 20507314
[TBL] [Abstract][Full Text] [Related]
33. Azacitidine: activity and efficacy as an epigenetic treatment of myelodysplastic syndromes.
Santini V
Expert Rev Hematol; 2009 Apr; 2(2):121-7. PubMed ID: 21083445
[TBL] [Abstract][Full Text] [Related]
34. Novel therapies for myelodysplastic syndromes.
Faderl S; Kantarjian HM
Cancer; 2004 Jul; 101(2):226-41. PubMed ID: 15241818
[TBL] [Abstract][Full Text] [Related]
35. Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome.
de Lima M; Giralt S
Semin Hematol; 2006 Apr; 43(2):107-17. PubMed ID: 16616044
[TBL] [Abstract][Full Text] [Related]
36. Nucleoside analogs and antimetabolite therapies for myelodysplastic syndrome.
Foss FM
Best Pract Res Clin Haematol; 2004 Dec; 17(4):573-84. PubMed ID: 15494295
[TBL] [Abstract][Full Text] [Related]
37. Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Nachtkamp K; Kündgen A; Strupp C; Giagounidis A; Kobbe G; Gattermann N; Haas R; Germing U
Leuk Res; 2009 Aug; 33(8):1024-8. PubMed ID: 19185917
[TBL] [Abstract][Full Text] [Related]
38. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.
Silverman LR; McKenzie DR; Peterson BL; Holland JF; Backstrom JT; Beach CL; Larson RA;
J Clin Oncol; 2006 Aug; 24(24):3895-903. PubMed ID: 16921040
[TBL] [Abstract][Full Text] [Related]
39. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
40. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.
Kröger N; Brand R; van Biezen A; Cahn JY; Slavin S; Blaise D; Sierra J; Zander A; Niederwieser D; de Witte T;
Bone Marrow Transplant; 2006 Jan; 37(2):183-9. PubMed ID: 16299545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
